Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Pfizer describes new MAP4K1 inhibitors

Nov. 25, 2021

Restoring cellular miR-127-3p inhibits herpesvirus-induced tumorigenesis in vitro and in vivo

Nov. 24, 2021

Novel CDK9 inhibitors as candidates for the treatment of acute myeloid leukemia

Nov. 24, 2021

Animal model recapitulates CCA susceptibility in progressive biliary injury and fibrosis

Nov. 24, 2021

Rhizen Pharmaceuticals synthesizes new PARP inhibitors

Nov. 24, 2021

Novartis synthesizes HIF-2alpha inhibitors

Nov. 24, 2021

Idorsia Pharmaceuticals patents CCR6 antagonists

Nov. 24, 2021

GNE-502 shows promising efficacy in breast tumor xenograft model

Nov. 24, 2021

KAND-145 + cisplatin reduces tumor size in disease model of chemotherapy-resistant ovarian cancer

Nov. 23, 2021

Bristol Myers Squibb adds structurally diverse compounds to BET inhibitor candidates

Nov. 23, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 7, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Hyperexcitability may be joint problem in epilepsy, dementia
BioWorld
The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
In the clinic for July 6, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Arcus, Genentech, Merck, Myriad, Otsuka, Partner, Revolution, Treos.